Premium
Comparison of Spectralis Fourier‐domain optical coherence tomography (OCT) and time‐domain Stratus OCT for the evaluation of macular thickness in patients with diabetes mellitus type 2
Author(s) -
GIL ARRIBAS L,
IDOIPE M,
GARCIA MARTIN E,
PINILLA I,
FUERTES I
Publication year - 2009
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.442.x
Subject(s) - medicine , optical coherence tomography , ophthalmology , diabetic retinopathy , diabetes mellitus , retinal , type 2 diabetes mellitus , endocrinology
Purpose To compare spectralis fourier‐domain OCT with Stratus Time‐Domain OCT for measuring macular thickness in patients with diabetes mellitus type 2 without retinopathy. Methods Prospective study of 49 patients with diabetes type 2. Twenty‐one men (42.9%) and twenty‐eight women (57.1%) were included. One eye by each patient was ramdomly included in the study. All of them were underwent three macular 512x128 volume cube scans with the Spectralis OCT system and with the Stratus OCT. The average of all the scans was calculated. The macular values of the nine areas corresponding to the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol were compared between the two systems. Results We found statistically significant differences in all macular measures between the two systems (p<0.001). The average of macular thickness measured with Spectralis OCT was approximately 266.84 µm (± 12.22). The average of macular thickness using Stratus OCT was 194.56 µm (± 12.04). The difference of foveal values between both devices was approximately 72.28 µm (± 9.67). Retinal thickness values were higher with Spectralis OCT Conclusion Macular measurements using Spectralis OCT are higher than those measured with Stratus OCT in patients with diabetes mellitus type 2. The results are comparable with the results obtained between Stratus OCT and Cirrus‐HD OCT in the same conditions and with the same sample of patients and with the values obtained in healthy subjects.